Using [68Ga]Ga-PSMA-11 PET/CT to monitor treatment response in prostate cancer patients can offer important lesion-based insights over prostate-specific membrane antigen (PSMA)-based monitoring, according to a new study published in EJNMMI Research.

The Department of Energy (DOE)’s National Nuclear Security Administration has issued a fourth, and final, cooperative agreement to Corvallis, Oregon-based Northwest Medical Isotopes, LLC.

In July, SHINE was one of three companies to receive $15 million in funding from the Department of Energy (DOE)’s National Nuclear Security Administration to bolster its production of molybdenum-99 (Mo-99).

The Penn PET Addiction Center of Excellence (PACE) will harness the minds of radiology and psychiatry researchers to better understand opioid use disorder and develop improvement treatment options.

A skin test may help clinicians prevent adverse drug reactions in patients receiving radiocontrast material, according to a new study published in the American Journal of Roentgenology.

The U.S. Nuclear Regulatory Commission (NRC) is asking for comments on its proposed revision to be submitted by Aug. 26.

New research suggests that fluorodeoxyglucose (FDG) PET is better for assessing the severity of Alzheimer’s disease and mild cognitive impairment (MCI) than florbetapir-PET scans.

A recent story in the New York Times analyzed the positives and potential negatives of undergoing an amyloid PET scan to gain insight into one’s risk of developing Alzheimer’s.

The American Society of Radiologic Technologists (ASRT) voiced their support for recent legislation that seeks to improve patient-access to radiopharmaceuticals in an Aug. 1 statement.

Researchers compared prostate-specific membrane antigen (PSMA) PET/CT to traditional 18F-fluciclovine PET/CT for the detection of biochemically recurrent prostate cancer.

A team of Japan-based researchers have created a medical camera capable of detecting and imaging radiotracers used in both PET and SPECT scans with limited radiation dosage.

An Australian Nuclear Science and Technology Organization (ANSTO) spokesman told the Australian the increase will be anywhere from 3-9%.